PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells

Alexandra Rogue (1, 2) , Sébastien Anthérieu (1) , Aurore Vluggens (1) , Thierry Umbdenstock (3) , Nancy Claude (4) , Catherine de La Moureyre-Spire (2) , Richard J Weaver (2) , André Guillouzo (1)

1 Foie, métabolismes et cancer
2 Biologie Servier
3 Technologie Servier
4 Institut de Recherches Servier

Although non-alcoholic fatty liver disease (NAFLD) is currently the most common form of chronic liver disease there is no pharmacological agent approved for its treatment. Since peroxisome proliferator-activated receptors (PPARs) are closely associated with hepatic lipid metabolism, they seem to play important roles in NAFLD. However, the effects of PPAR agonists on steatosis that is a common pathology associated with NAFLD, remain largely controversial. In this study, the effects of various PPAR agonists, i.e. fenofibrate, bezafibrate, troglitazone, rosiglitazone, muraglitazar and tesaglitazar on oleic acid-induced steatotic HepaRG cells were investigated after a single 24-hour or 2-week repeat treatment. Lipid vesicles stained by Oil-Red O and triglycerides accumulation caused by oleic acid overload, were decreased, by up to 50%, while fatty acid oxidation was induced after 2-week co-treatment with PPAR agonists. The greatest effects on reduction of steatosis were obtained with the dual PPARα/γ agonist muraglitazar. Such improvement of steatosis was associated with up-regulation of genes related to fatty acid oxidation activity and down-regulation of many genes involved in lipogenesis. Moreover, modulation of expression of some nuclear receptor genes, such as FXR, LXRα and CAR, which are potent actors in the control of lipogenesis, was observed and might explain repression of de novo lipogenesis. CONCLUSION: Altogether, our in vitro data on steatotic HepaRG cells treated with PPAR agonists correlated well with clinical investigations, bringing a proof of concept that drug-induced reversal of steatosis in human can be evaluated in in vitro before conducting long-term and costly in vivo studies in animals and patients.

Domaines: Pharmacologie

Alexandra Rogue, Sébastien Anthérieu, Aurore Vluggens, Thierry Umbdenstock, Nancy Claude, et al.. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. Toxicology and Applied Pharmacology, 2014, 276 (1), pp.73-81. ⟨10.1016/j.taap.2014.02.001⟩. ⟨hal-01020611⟩